Zoledronic acid Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
N/0028 
Minor change in labelling or package leaflet not 
17/09/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0026 
B.II.b.3.a - Change in the manufacturing process of 
04/05/2021 
n/a 
the finished or intermediate product - Minor change in 
the manufacturing process 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IB/0027 
B.II.e.4.c - Change in shape or dimensions of the 
19/04/2021 
n/a 
container or closure (immediate packaging) - Sterile 
medicinal products 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/09/2020 
22/01/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
II, Labelling 
and PL 
IB/0024 
C.I.7.b - Deletion of - a strength 
30/01/2020 
22/01/2021 
IB/0023/G 
This was an application for a group of variations. 
05/09/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.e - Change in test procedure for AS or starting 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
B.I.c.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Addition of a new specification parameter to the 
specification with its corresponding test method 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
B.I.a.4.c - Change to in-process tests or limits applied 
during the manufacture of the AS - Deletion of a 
non-significant in-process test 
B.I.b.2.b - Change in test procedure for AS or starting 
material/reagent/intermediate - Deletion of a test 
procedure for the AS or a starting 
material/reagent/intermediate, if an alternative test 
procedure is already authorised 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
Page 3/10 
 
 
 
 
 
 
IA/0022 
A.7 - Administrative change - Deletion of 
08/08/2019 
09/12/2019 
Annex II and PL 
manufacturing sites 
IB/0021 
B.I.b.2.e - Change in test procedure for AS or starting 
17/12/2018 
n/a 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
IA/0020 
A.7 - Administrative change - Deletion of 
27/02/2018 
28/09/2018 
Annex II and PL 
manufacturing sites 
IB/0019 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
06/10/2017 
28/09/2018 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
R/0018 
Renewal of the marketing authorisation. 
23/03/2017 
22/05/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Zoledronic acid Teva in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0017 
B.II.e.2.z - Change in the specification parameters 
18/10/2016 
n/a 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IB/0016 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
25/08/2016 
22/05/2017 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/12/2015 
11/02/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/10/2015 
11/02/2016 
SmPC, Annex II 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
and PL 
IA/0013/G 
This was an application for a group of variations. 
11/05/2015 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a 
non-significant specification parameter (e.g. deletion 
of an obsolete parameter) 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
corresponding test method 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0012/G 
This was an application for a group of variations. 
19/02/2015 
11/02/2016 
SmPC and PL 
Update of sections 4.4 and 4.5 of the SmPC to add 
information on additive effect of 
hypocalcaemia-causing medicinal products;  
Update of section 4.6 of the SmPC to add information 
for women of child-bearing potential;  
Update of section 4.8 of the SmPC to change 
frequency of uveitis (from "very rare" to "rare"); and  
Update of section 5.2 of the SmPC to revise the text on 
plasma protein binding. 
Furthermore. editorial changes are made to update 
some adverse reaction terms in section 4.8 of the 
SmPC according to MedDRA preferred terms. The 
Page 6/10 
 
 
 
 
 
 
 
 
Package Leaflet is updated accordingly. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
T/0011 
Transfer of Marketing Authorisation 
08/12/2014 
19/12/2014 
SmPC, 
Labelling and 
PL 
Page 7/10 
 
 
 
 
 
 
 
 
 
X/0008 
To include a new pharmaceutical form 
24/07/2014 
01/10/2014 
SmPC, Annex 
For further information, please refer to the Assessment 
II, Labelling 
Report Zoledronic acid-H-2439-X-08-AR-en. 
Annex I_2.(d) Change or addition of a new 
and PL 
pharmaceutical form 
IAIN/0010 
B.II.b.2.c.2 - Change to importer, batch release 
30/04/2014 
27/06/2014 
Annex II and PL 
arrangements and quality control testing of the FP - 
Including batch control/testing 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/03/2014 
27/06/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
IA/0007/G 
This was an application for a group of variations. 
16/12/2013 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
B.I.c.3.b - Change in test procedure for the immediate 
packaging of the AS - Other changes to a test 
procedure (including replacement or addition) 
IAIN/0006 
C.I.z - Changes (Safety/Efficacy) of Human and 
16/07/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/07/2013 
27/06/2014 
SmPC, Annex II 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
and PL 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/01/2013 
27/06/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0002/G 
This was an application for a group of variations. 
04/12/2012 
n/a 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
IAIN/0001 
B.II.b.1.a - Replacement or addition of a 
19/10/2012 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
